6th Jul 2005 07:00
Advanced Medical Solutions Grp PLC06 July 2005 For immediate release 6th July 2005 Advanced Medical Solutions Group plc ("AMS" or "the Company") Launches superglue product for closing keyhole surgery wounds Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the globalwoundcare technology company, today announces that it has introduced a novelproduct for use in closing wounds after keyhole (laparoscopic) surgerythroughout Europe. The product, LiquiBand Laparoscopic(TM), will form part of the family of medicaladhesives based on superglue technology sold by AMS through its MedLogic woundclosure division. These products which are sold direct to hospitals in the UKand through marketing and distribution partners throughout the rest of Europe,such as Baxter Healthcare in France and Spain and Resorba Clinicare in Germany,are used to close wounds in the Accident and Emergency (A&E) department and inoperating theatres, instead of the conventional use of sutures and staples. AMS is market leader in the use of skin closure glues in A&E in the UK under theLiquiBandTM brand, and has introduced a product designed for use in closingsurgical incisions in the operating theatre (LiquiBand SurgicalTM). It is estimated that there are currently around 1 million procedures performedby laparoscopic surgery in Europe. These include many gynaecological proceduresand routine general surgery operations such as gall bladder removal and herniarepair where the use of minimally invasive surgery offers real benefit to thepatient, surgeon and healthcare systems. The subsequent closure of these smallincisions with glue offers major benefits over the use of conventional methodssuch as sutures and staples. LiquiBand Laparoscopic(TM) is a two-part adhesive system and combines fast,strong, secure closure of the skin whilst providing occlusive wound protectionresulting in reduced trauma, reduced risk of infection, excellent cosmeticoutcomes and no sutures or staples to remove. The new product was introduced at a major meeting in the UK attended bymarketing and distribution partners and surgeons from around Europe. The use ofthe product in a range of surgical procedures was demonstrated through livesurgery by UK surgeon champions. The product has subsequently been launched andis now available for sale in most countries throughout Europe. Commenting on today's announcement, Dr. Don Evans, Chief Executive of AMS, said:"LiquiBand Laparoscopic(TM) is an exciting new product that offers real clinicaland patient benefits for the closure of these small incisions resulting fromlaparoscopic procedures. As the number of these procedures continues toincrease, the potential for this product is significant as it should become thestandard of care. We are in an excellent position to lead this trend throughoutEurope on the back of our strong direct presence in the UK and our marketing anddistribution partners in the other major markets." - ENDS - For further information, please contact: Advanced Medical Solutions Group plc Tel : +44 (0) 1606 545508Don Evans, Chief ExecutiveMary Tavener, Finance Directorwww.admedsol.com Buchanan Communications Tel: +44 (0) 20 7466 5000Mark Court, Mary-Jane Johnson Notes to Editors: Advanced Medical Solutions is a leading company in the development andmanufacture of products for the $15 billion global woundcare market. Founded in 1991 and currently quoted on AIM, Advanced Medical Solutions isfocused on the design, development and manufacture of innovative andtechnologically advanced products for woundcare and other medical applications. In-house natural and synthetic polymer technology is used to provide advancedwound dressings based on the moist healing principle. AMS's resources ensure aunique position as a vertically integrated 'one stop shop' to provide allcategories of moist wound healing products. The Company has the capability tomove from product design and development through to production and deliveryready for distribution into customer markets. The acquisition of MedLogic in 2002 has brought AMS products and technology incyanoacrylate based tissue adhesives that offer benefits over sutures andstaples for closing wounds sold direct to hospitals or through distributors. AMS's technology and products currently serve the majority of the key globalmarkets with strategic partners including 3M, Novartis, Johnson & Johnson,Molnlycke Healthcare, Smith + Nephew and Cardinal Health. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Advanced Medical Solutions Group